Newsroom | 33745 results

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa de oncologia global, anunciou hoje os resultados financeiros e as atualizações corporativas do segundo trimestre de 2025. "Nosso sólido desempenho no segundo trimestre reforça nossa trajetória como uma potência global em oncologia e destaca nossa habilidade comprovada de proporcionar crescimento sustentável e a longo prazo", afirmou John V. Oyler, cofundador, presidente e CEO da BeOn...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the issuance of inducement awards to three new hires, as required under Nasdaq Listing Rule 5635(c)(4)....

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron’s new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. The stock options were granted on August 7, 2025. The stock options have an exercise price of $1.30 per share, wh...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the UBS Precision Medicine Frontiers Summit...

DUBLIN--(BUSINESS WIRE)--The "Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering. The Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnost...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2025. “We remain focused on exploring strategic alternatives and partnerships across our portfolio to enhance long-term shareholder value, as exemplified by our recent worldwide licensing agreement with Debiopharm for lunresertib and out-licensing of early-stage disco...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.（NASDAQ：ONC、HKEX：06160、SSE：688235）は、2025年第2・四半期の財務結果および企業最新情報を発表しました。 「第2・四半期の力強い業績は、グローバルなオンコロジー分野のリーダーとしての当社の軌道をさらに確かなものにし、持続的かつ長期的な成長を実現する確かな能力を裏付けるものとなっています」と、BeOneの共同創業者兼会長兼最高経営責任者（CEO）であるジョン・V・オイラーは述べました。「私たちは明確な目的を持って取り組み、世界中のより多くの患者さんに革新的な医薬品を届けるという使命を前進させています。当社の血液がん領域の中核を担う製品であるBRUKINSAは承認された適応数が最も多く、クラス最高のBTK阻害剤として引き続き標準を打ち立てており、5つの適応における優れた有効性、良好な安全性、そして肯定的な患者転帰によって、米国市場でリーダーの地位を確立しています。この勢いを背景に、当社の第3...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una compañía global de oncología, anunció hoy los resultados financieros y novedades corporativas del segundo trimestre de 2025. “El sólido desempeño en el segundo trimestre refuerza nuestra trayectoria como potencia mundial en oncología y subraya nuestra capacidad demostrada para lograr un crecimiento sostenible a largo plazo”, afirmó John V. Oyler, cofundador, presidente y CEO de BeOne. Estamos...